Dexamethasone in the treatment of hypernatraemic dehydration

KHALID N HAQUE
Faculty of Medicine, Riyadh, Saudi Arabia

SUMMARY Ninety infants with severe hypernatraemic dehydration (plasma sodium > 150 mmol/l) were studied. Most had had a convolution before admission. They were allocated to two treatment groups. Both groups received intravenous plasma followed by slow intravenous rehydration and correction of acidosis. In addition, one group received intramuscular phenobarbitone, the other group received dexamethasone 0.3 mg by intramuscular injection every 6 hours for 48 hours. Fewer infants receiving dexamethasone had convulsions during treatment (18% compared with 52%), and fewer (18%) of them died than in the group who did not receive dexamethasone (40%). Dexamethasone may have a role in the management of hypernatraemic dehydration in infants.

Since the introduction of low-solute milks the incidence of hypernatraemic dehydration has fallen in western countries; however in developing countries ignorance and the increasing use of dried cows' milk has resulted in a large number of cases with high morbidity and mortality. Generally a child is brought to hospital having had at least one convolution before arrival. As the risk of further convulsions was not being reduced by our standard treatment, it was decided to use dexamethasone in an attempt to reduce cerebral oedema and prevent further convulsions.

Patients and methods

During an 11-month period, 90 infants suffering from hypernatraemic dehydration (plasma sodium >150 mmol/l and a calculated plasma osmolality >350 mmol/kg) were studied. None of the infants was known to have a history of cerebral or renal abnormality; each had been admitted with gastroenteritis and had moderate or severe dehydration—that is 10 or 15%. Each infant was allotted alternately to one of two treatment groups (Table 1). Each had a lumbar puncture to exclude meningitis (2 cases were excluded), 4 infants had pneumonia in addition to gastroenteritis, and are included in the study. Infants were weighed on admission and then daily. Plasma urea, electrolytes, calcium, and glucose were measured on admission and then daily, or more frequently if necessary. Neurological state was graded according to Banister—that is 0 = nothing unusual; 1 = irritable, or poorly responsive and irritable when disturbed; 2 = increased tone with or without neck stiffness; 3 = jittery movements, with or without nystagmoid eye movements; 4 = convulsing.

<table>
<thead>
<tr>
<th>Table 1 Treatment regimen</th>
</tr>
</thead>
<tbody>
<tr>
<td>All infants</td>
</tr>
<tr>
<td>If circulatory failure, intravenous plasma (20–30 ml/kg) was given promptly</td>
</tr>
<tr>
<td>Intravenous 0-1.8% saline in 5% dextrose at 100 ml/kg per 24 hours corrected weight. (If oral intake introduced then the infusion rate was reduced accordingly but the total amount of fluid given over 24 hours remained the same)</td>
</tr>
<tr>
<td>Acidosis half corrected by 8-4% sodium bicarbonate if base deficit &gt;10 mmol/l or if standard bicarbonate &lt;13 mmol/l</td>
</tr>
<tr>
<td>Potassium chloride 26 mmol/l added when urine passed by the patient unless level of plasma potassium was high</td>
</tr>
<tr>
<td>Group 1</td>
</tr>
<tr>
<td>Phenobarbitone 15 mg intramuscularly every 12 hours</td>
</tr>
<tr>
<td>Group 2</td>
</tr>
<tr>
<td>Dexamethasone 0.3 mg intramuscularly every 6 hours</td>
</tr>
</tbody>
</table>

Results

Details of patients and their investigations are shown in Table 2. There were 45 infants in each group, all of them were 10% or more dehydrated, thus all required initial plasma resuscitation. 84% had convulsed before admission. After admission 18% of infants in group 2 (who had dexamethasone) had one or more convulsions compared with 52% in group 1 (Table 3).

Hypocalcaemia. In only 2 infants did the plasma calcium fall below 7 mg/100 ml (1.75 mmol/l); neither infant showed any sign of hypocalcaemia.
Hypernatraemia. 13% of infants had high levels of blood sugar (>200 mg/100 ml; >11·1 mmol/l) none was given insulin, and the level of blood glucose fell rapidly during rehydration.

Anaemia. Most of the infants in this hospital are anaemic, and these 90 infants had a mean Hb of 8·6 (range 5·6–12·8) g/dl. 22 infants were each given a blood transfusion during their stay in hospital.

Discussion

Neurological complications dominate the clinical picture of hypernatraemic dehydration. The risk of permanent damage is greater in the young infant and in patients with serum sodium of 160 mmol/l or more. Permanent neurological deficit is said to occur in 11 to 15% of such infants. Convulsions in hypernatraemia are thought to be due to cerebral oedema.

Our trial showed that dexamethasone used in conjunction with slow rehydration (0·18% saline in 5% dextrose) was associated with fewer convulsions and a lower mortality rate. It seems that the mortality rate may be related to reduction of the cerebral oedema. Our mortality rates are still unacceptably high but this is due mainly to the delay in the infants coming to the hospital; 84% had convulsed before coming to the hospital. Nevertheless, the 18% mortality rate of the dexamethasone group is similar to that reported 16 years ago in the UK. This is remarkable since most of our infants arrived in moribund condition or were malmourished.

Although we feel that dexamethasone may have a role in the management of hypernatraemic dehydration, the best answer lies in prevention and in trying to undo the damage which bottle feeding has caused in developing countries. Further education of the mothers is needed together with restriction of high-solute milk products.

I thank Dr Hussain Showail, Director General, Maternity and Children's Hospital, for allowing me to do this study, my junior colleagues, and the nursing staff.

References


Correspondence to Dr Khalid Haque, Faculty of Medicine, PO Box 2925, Riyadh, Saudi Arabia.

Received 5 December 1979
Dexamethasone in the treatment of hypernatraemic dehydration.

K N Haque

Arch Dis Child 1981 56: 223-224
doi: 10.1136/adc.56.3.223

Updated information and services can be found at:
http://adc.bmj.com/content/56/3/223

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/